Treatment of HIV-related primary central nervous system lymphoma with azt high dose, HAART, interleukin-2 and foscarnet in three patients
Tóm tắt
Combined immunomodulatory and antiviral treatment was administered to three patients with newly diagnosed HIV-associated primary central nervous system lymphoma (PCNSL) in an attempt to improve outcomes. Three patients from our institution who were recently diagnosed with HIV-associated PCNSL received intravenous azidothymidine (AZT) 1.6 gr. bid for two weeks, followed by oral AZT 250 mg bid from day 15. In addition, complementary highly active antiretroviral therapy (HAART) with a second nucleoside reverse transcriptase inhibitor (NRTI) plus one protease inhibitor (PI) and interleukin 2 (IL-2) subcutaneously 2 million units twice daily (bid) plus foscarnet 90 mg/kg bid were administered on days 1-14. One patient received anti-EpsteinBarr virus (EBV)-maintenance therapy with ganciclovir, followed by cidofovir [1]. All patients experienced progressive disease while on induction therapy, and switched early to whole-brain radiation therapy (WBRT) as second linetreatment. No grade 3 or 4 toxicities were observed. Two patients died on days 50 and 166 respectively due to progressive disease. The third patient with histologically proven lymphoproliferation and only suspected PCNSL remained alive at 53 months. He was on HAART and remained clinically and neurologically stable. Although IL-2, HAART, high-dose AZT and foscarnet are used for other HIV-related conditions, they did not demonstrate benefit in lymphoma remission for 2 HIVassociated PCNSL patients. The third patient went into delayed remission after additional radiotherapy and was in good clinical and neurological health status over 53 months after diagnosis.
Tài liệu tham khảo
Raez L, Cabral L, Cai JP, et al.: Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999, 15: 713–719. 10.1089/088922299310809
Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005, 10: 412–426. 10.1634/theoncologist.10-6-412
Wolf T, Brodt HR, Fichtlscherer S, et al.: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005,46(2):207–15. 10.1080/10428190400015733
Hoffmann C, Tabrizian S, Wolf E, et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001, 15: 2119–2127. 10.1097/00002030-200111090-00007
Aboulafia DM, Ratner L, Miles SA, et al.: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006, 6: 399–402. 10.3816/CLM.2006.n.017
Kreisl T, Panageas K, Elkin E, et al.: Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008, 25: 1–7.
Batchelor T, Loeffler JS: Primary CNS lymphoma. J Clin Oncol 2006, 24: 1281–1288. 10.1200/JCO.2005.04.8819
Omuro AMP, Abrey LE: Chemotherapy for primary Central Nervous System Lymphoma. Neurosurgical Focus 2006,21(5):E12. 10.3171/foc.2006.21.5.13
DeAngelis LM, Iwamoto F: An Update on Primary Central Nervous System Lymphoma. Hematology 2006, 1: 311–16. 10.1182/asheducation-2006.1.311
Gavrilovic IT, Hormigo A, Yahalom J, et al.: Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma. J Clin Oncol 2006,1(24):4570–4. 10.1200/JCO.2006.06.6910
Illerhaus G, Marks R, Ihorst G, et al.: High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractioned Radiotherapy As First-Line Treatment of Primary CNS Lymphoma. J Clin Oncology 2006, 24: 1–8. 10.1200/JCO.2005.03.7234
Soussain C, Suzan F, Hoang-Xuan K, et al.: Results of intensive chemotherapy followed by hematopoietic stemcell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001,19(3):742–749. (follow-up Soussain, 2008 JCO 26: 2512–18)
Cheng T, Forsyth P, Chaudhry A, et al.: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplantation 2003, 31: 679–685. 10.1038/sj.bmt.1703917
Illerhaus G, Markert A, Feuerhake F, et al.: Immuno-Chemotherapy with Rituximab, Methotrexate, CCNU and Procarbazine for the treatment of Primary CNS-Lymphoma in the Elderly. Onkologie 2008,31(suppl 4):11.
Skiest DJ, Crosby C: Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003,17(12):1787–93. 10.1097/00002030-200308150-00007
Chamberlain MC, Kormanik PA: AIDS-related central nervous system lymphomas. J Neurooncol 1999, 43: 269–276. 10.1023/A:1006262720665
Baumgartner JE, Rachlin JR, Beckstead JH, et al.: Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990, 73: 206–211. 10.3171/jns.1990.73.2.0206
Diamond C, Taylor TH, Aboumrad T, et al.: Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006,106(1):128–35. 10.1002/cncr.21562
Re A, Tucci A, Casari S, et al.: Treating Lymphoma with Curative Intent in HIV Positive Patients after the Advent of HAART. A Comparative Analysis with the HIV Negative Population ASH Poster Board 2008, III-685. 3603
Aboulafia DM, Puswella AM: Case Report: Highly Active Antiretroviral Therapy as the Sole Treatment for AIDS-Related Primary Central Nervous System Lymphoma: A Case Report with Implications for Treatment. AIDS Patient Care and STDs 2007,21(12):900–907. 10.1089/apc.2007.0009
Chotmongkol V, Pesee M: AIDS-Related Primary Central Nervous System Lymphoma: Prolonged Remission Associated with Highly Active Antiretroviral Therapy. J Med Assoc Thai 2002, 85: 634–637.
McGowan JP, Shah S: Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 1998, 12: 952–54.
Corales R, Taege A, Rehm S, et al.: Regression of AIDS-related CNS lymphoma with HAART XIII International AIDS Conference. Durban 2000. (abstract MoPpB1086)
Fischer L, Thiel E, Klasen HA, et al.: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006,17(7):1141–5. 10.1093/annonc/mdl070
Bossolasco S, Falk KI, Ponzoni M, et al.: Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis 2006, 42: 21–25. 10.1086/498508
Hänel M, Fiedler F, Thorns C: Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement. Onkologie 2001,24(5):491–494. 10.1159/000055132
Gershburg E, Pagano JS: Epstein-Barr virus infections: prospects for treatment. J Antimicrobial Chemotherapy 2005,56(2):277–281. 10.1093/jac/dki240
Oertel SH, Riess H: Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res 2002, 159: 89–95. 10.1007/978-3-642-56352-2_11
Burighel N, Ghezzi S, Nozza S, et al.: Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica 2006, 91: 244–247.
Abrams D, Levy Y, Tambussi G, et al.: Interleukin-2 Therapy in Patients with HIV Infection. N Engl J Med 2009, 361: 1548–59. 10.1056/NEJMoa0903175
Maggiorella L, Wen B, Frascogna V, et al.: Combined radiation sensitizing nd anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res 2005,25(6B):4357–62.
Jacomet C, Girard PM, Lebrette MG, et al.: Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997, 11: 1725–30. 10.1097/00002030-199714000-00009
Herrlinger U, Korfel A, Hebart H, et al.: Meeting Report: Primary Central Nervous System Lymphoma: Standards Of Care And Future Perspectives. Onkologie 2005, 28–2: 109–111. Congress Report 10.1159/000083374
Antonini G, Cox MC, Montefusco E, et al.: Intrathecal CD-20 antibody an effective and safe treatment for leptomeningeal lymphoma. J Neuro-Oncology 2007,81(2):197–199. 10.1007/s11060-006-9217-y
Pels H, Schulz H, Schlegel U, et al.: Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature. Onkologie 2003, 26: 351–354. 10.1159/000072095
Rubenstein JL, Fridlyand J, Abrey L, et al.: Phase 1 Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma. J Clin Oncology 2007,25(11):1350–1356. 10.1200/JCO.2006.09.7311
Abrey LE, Craig H, Moskowitz WPM, et al.: Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis. J Clin Oncology 2003,21(22):4151–4156. 10.1200/JCO.2003.05.024
Omuro AMP, Taillandier L, Chinot O, et al.: Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neuro-Oncology 2007,85(2):207–211. 10.1007/s11060-007-9397-0
Sakamoto M, Oya N, Mizowaki T, et al.: Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas. J Neurooncol 2006, 77: 53–58. 10.1007/s11060-005-7698-8
Newell ME, Hoy JF, Cooper SG, et al.: Human immunodeficiency virus-related primary central nervous system lymphoma. Factors influencing survival in 111 patients Cancer 2004,100(12):2627–2636.